Physician profile
Robert W Balsiger
NPI 1083935811
$13,426.58
in general payments reported to CMS, 2019-2025
68 companies · $2,498 in 2025
The $2,498 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,920 · 2020: $351 · 2021: $1,239 · 2022: $2,457 · 2023: $2,535 · 2024: $2,426 · 2025: $2,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,308 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,308.19 |
| Education | $150.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,014.68 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,400.97 | 2019-2025 | |
| Pfizer INC. | $883.78 | 2019-2025 | |
| Amgen INC. | $531.20 | 2019-2025 | Uplizna |
| Ucb, INC. | $471.81 | 2019-2025 | Rystiggo, Briviact |
| Teva Pharmaceuticals USA, INC. | $459.88 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Allergan, INC. | $373.09 | 2019-2022 | |
| Genentech USA, INC. | $356.15 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $288.65 | 2019-2024 | Ultomiris, Soliris |
| Emd Serono, INC. | $280.16 | 2019-2023 | Mavenclad |
| Abbott Laboratories | $263.44 | 2019-2023 | Amplatzer Amulet |
| Biohaven Pharmaceutical Holding Company LTD. | $228.37 | 2022 | |
| Horizon Therapeutics Plc | $202.41 | 2021-2023 | Uplizna |
| Sunovion Pharmaceuticals INC. | $191.27 | 2019-2022 | |
| Acclarent, INC | $186.81 | 2023 | Trudi Nav Cable |
Show all 66 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Balsiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.